Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c

Kathleen B. Schwarz, Jean P. Molleston, Maureen M. Jonas, Jessica Wen, Karen F. Murray, Philip Rosenthal, Regino P. Gonzalez-Peralta, Steven J. Lobritto, Douglas Mogul, Vedran Pavlovic, Charles Warne, Cynthia Wat, Bruce Thompson

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Objectives: No long-term data have been published on the durability of response following pegylated interferon (PegIFN) treatment in children with chronic hepatitis C. This prospective, multicenter, long-term follow-up (LTFU) study aimed to assess long-term durability of sustained virological response (SVR), long-term safety and tolerability, and the association between IL28B genotype and treatment response, in children previously treated with PegIFN alfa-2a±ribavirin (RBV) in the PEDS-C trial. Methods: A total of 93 patients were assessed for enrollment, and 38 enrolled in the study. Patients attended 2 study visits: 5 (mean 5.6, range 4.1-6.6) and 6 (6.6, 5.1-7.7) years after treatment cessation. Standardized medical history, physical examination, and laboratory testing were performed at these visits. Reminder telephone calls were conducted at 4 and 8 months after the initial visit. Results: The LTFU cohort was the representative of the original PEDS-C cohort because both baseline and treatment characteristics were comparable. Of the 38 participants, 21 achieved SVR (responders) during the PEDS-C trial and 17 had not (nonresponders). All 21 responders maintained undetectable hepatitis C virus RNA during the LTFU (4.4-7.0 years after achieving SVR) in contrast to the nonresponders who demonstrated persistent viremia. IL28B CC genotype was associated with SVR (67% vs 30% in non-CC, P =0.028). Conclusion: Long-term durability of SVR is excellent following PegIFN alfa-2a treatment in children with chronic hepatitis C; SVR is higher in those with IL28B CC versus non-CC.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalJournal of pediatric gastroenterology and nutrition
Volume62
Issue number1
DOIs
StatePublished - 2016

Keywords

  • PEDS-C study
  • antiviral therapy
  • long-term follow-up
  • pediatric viral hepatitis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Fingerprint Dive into the research topics of 'Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c'. Together they form a unique fingerprint.

  • Cite this

    Schwarz, K. B., Molleston, J. P., Jonas, M. M., Wen, J., Murray, K. F., Rosenthal, P., Gonzalez-Peralta, R. P., Lobritto, S. J., Mogul, D., Pavlovic, V., Warne, C., Wat, C., & Thompson, B. (2016). Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c. Journal of pediatric gastroenterology and nutrition, 62(1), 93-96. https://doi.org/10.1097/MPG.0000000000000929